NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
21/03/2023
Voltar para busca
Dado oficial do USPTO
BORA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
21/03/2023
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
04/11/2020
Data de registro
21/03/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/03/2023
Última transação
21/03/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
5
Tipo de titular
99
Localização do titular
Taipei City, TW
Examinador
FRIEDMAN, LESLEE ANN
Unidade examinadora
N20
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the stylized letters "BORA".
Titulares e representantes
Titulares
BORA PHARMACEUTICALS CO., LTD.
Representantes
Hui Zhang RABIN & BERDO, P.C.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Nutritional supplements; Antiallergic medicines; Sulphonamides as medicines; Medicines for intestinal disorders; Medicines for dental purposes; Medicines for alleviating constipation; Motion sickness medicines; Medicines for the treatment of gastrointestinal diseases; Prescription and non-prescription medicinespillstabletscapsulescapletsliquid dropssachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Ocular pharmaceuticals; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Anti-diabetic pharmaceuticals; Pharmaceuticalspsychotropics; Pharmaceuticalsantihelmintics; Pharmaceuticalsanti-infectives; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticalsinducers of erections; Injectable pharmaceuticals for treatment of anaphylactic reactions; Pharmaceuticalslipid lowering agents; Antimicrobial preparations for inhibiting microbiological decomposition in foodbeveragesanimal feed and pharmaceuticals; Astringents for medicinal purposes; Pharmaceutical preparations for wounds; Dermatological pharmaceutical products; Pharmaceutical skin lotions; Pharmaceutical preparationsantivirals; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for skin care; Pharmaceutical preparationsantidepressants; Pharmaceutical preparations for use in urology; Pharmaceutical products and preparations for chloasma; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating diabetes; Pharmaceutical solutions used in dialysis; Pharmaceutical products for ophthalmological use; Anti-epileptic pharmaceutical preparations; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating hypertension; Pharmaceutical antitussive-cold preparations; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparationsanticoagulants; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating halitosis; Effervescent analgesic pharmaceutical preparations; Pharmaceutical products for the prevention and treatment of cancer; Analgesic and muscle relaxant pharmaceutical preparations; Pharmaceutical preparationsappetite suppressants; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting sensory organs; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparationsinjectable contraceptives; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products for the treatment of joint disease; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the relief of insect bites; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for treating allergic rhinitis; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparationsan analgesic for human consumption taken orally; Pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical preparationsa topical preparation for the treatment of ocular disorders prescribed by ophthalmologistseye surgeonsoptometrists; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorderssports related injuriesfor knee cartilage regeneration; Pharmaceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disordersdiabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesfor the treatment of bacteria-based diseasesfor the treatment of diabetesanti-infective preparationsantiviral preparationsantibioticsantifungal preparations and vaccines; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary system; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for use in dermatologyoncologyhematology and in tissue and organ transplantationin ophthalmology and for gastroenterological disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
21/03/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/01/2023
PUBO
PUBLISHED FOR OPPOSITION
03/01/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/12/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
30/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/11/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/11/2022
ALIE
ASSIGNED TO LIE
08/11/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
01/11/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
16/05/2022
GNSL
LETTER OF SUSPENSION E-MAILED
16/05/2022
CNSL
SUSPENSION LETTER WRITTEN
16/05/2022
DOCK
ASSIGNED TO EXAMINER
16/05/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/05/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/05/2022
ALIE
ASSIGNED TO LIE
12/05/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
10/05/2022
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/12/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/12/2021
CNSI
SUSPENSION INQUIRY WRITTEN
11/12/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
22/11/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
20/05/2021
GNSL
LETTER OF SUSPENSION E-MAILED
20/05/2021
CNSL
SUSPENSION LETTER WRITTEN
20/05/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/04/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/04/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/04/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/04/2021
GNRT
NON-FINAL ACTION E-MAILED
10/04/2021
CNRT
NON-FINAL ACTION WRITTEN
10/04/2021
DOCK
ASSIGNED TO EXAMINER
09/04/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/01/2021
NWAP
NEW APPLICATION ENTERED
07/11/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BORA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.